Discovery and validation of genetic determinants of type 1 diabetes
T1DM is partly genetically determined and more than 50 associated genetic loci have been identified with the HLA region on chromosome 6 having the major role.(4) These 4 discoveries yielded insights into the potential pathways causing diabetes some of which are now being targeted by novel intervention therapies, however more than 50 known genetic loci for T1DM do not explain all the known heritability with estimates of missing heritability varying from 20-80%.(5,6) Among several potential explanations for this "missing heritability" are the existence of rare variants with large effects and the existence of additional more common variants with effects too low to have been detected by sample sizes used so far. Existing genetic studies of T1DM have been based on around 12000 cases, which is many times lower than sample sizes in meta-analyses of genome-wide association studies (GWAS) for type 2 diabetes mellitus (T2DM).(4) Of note, almost all studies to date are in cohorts of childhood-onset T1DM, despite the fact that almost 50% of T1DM has its onset in adulthood. The largest study to date of older onset T1DM was limited to evaluation of already known loci in 1212 autoantibody positive adults with diabetes in which subtle age of onset effects were found for some loci. (7, 8) Thus, additional discovery work to detect new T1DM loci is warranted especially for those with older age of onset. We will conduct genome wide association studies using the SDRNT1BIO cohort and a background population representative control set of genotypes from Scotland.
Discovery and validation of genetic determinants of complications of T1DM
Many complications of diabetes are heritable (20-50% for retinopathy and nephropathy), justifying attempts to discover their genetic determinants.(9) Few unequivocal replicable genetic associations have been found, so large scale initiatives are underway although many have greater focus on T2DM than T1DM because of the greater prevalence and larger T2DM cohorts [www.imi-summit.eu]. The GENIE Consortium has focused on nephropathy in T1DM and a JDRF funded consortium on the genetics of nephropathy in T1DM is currently 5 underway.(10) For many other phenotypes of relevance in T1DM efforts to discover genetic determinants are sparse. For example, there is little genetic data on neuropathy, (11) propensity to hypoglycaemia, or diabetic ketoacidosis. Thus the GWAS data from the SDRNT1BIO will augment existing international efforts to understand the genetics of macroand micro-vascular complications of diabetes and will provide novel GWAS studies of neglected traits.
Pathogenesis and biomarkers of complications
Several extremely productive prospective cohort studies of T1DM have yielded much of what we know about the pathogenesis and risk factors for complications and how these differ between T1DM and T2DM. These include the EURODIAB PCS (n=2787) (12) , the Pittsburgh EDC (n=658) (13) , the DCCT/EDIC (n=1300) (14) , ORPS (n=554) (15) , and WESDR (n around 1000 (16) , CACTI (n around 656) (17) , and FinnDiane (n around 4500). (18) However, the total sample size and number of incident cases of complications across these cohorts does not provide adequate power for discovery efforts. Larger cohort studies in T1DM such as the Swedish National Diabetes Register, use regular reporting of risk factors from clinical sites and linkage to routine data but do not currently have any sample collection. (19) To fully exploit new 'omic methods for pathway and biomarker discovery, including lipidomics, metabolomics and genomics, and to develop more precise prediction algorithms for complications that incorporate new biomarkers, further large cohorts of T1DM patients are needed to supplement these existing excellent cohorts. With SDRNT1BIO, we decided to harness Scotland's e-health care record system, and the existence of a unique health care identifier across all records in Scotland, to enable the creation of a cohort in which extensive prospective routine data are automatically captured.
Stratification of apparent T1DM
The gold standard biomarker of endogenous insulin production is C-peptide concentrations.
Previously it was believed that those with T1DM have no residual insulin secretion. With the development of ultra-sensitive C-peptide assays, there is increasing realisation that detectable levels of C-peptide are much more common in T1DM than previously thought. (20, 21, 22) Exploring the genetic and immunological differences between those with and without detectable C-peptide might yield possible mechanisms for preserving beta cell function and preventing or even reversing T1DM; this is another question being addressed by the SDRNT1BIO. (23) Another aspect of diabetes stratification is the improved detection of maturity onset diabetes of the young (MODY) among those misdiagnosed as having T1DM. Diagnosis of MODY remains difficult and at present it is estimated only around 25% of all MODY are correctly diagnosed. (24) The data collected on family history, genotype, C-peptide and auto-antibody status, along with sequencing of potential cases, will allow us to compare the yield of cases from various detection algorithms.
Environmental and socio-economic determinants of T1DM
The environmental determinants of T1DM remain largely unknown (putative factors include infection e.g. congenital rubella, caesarean section, older maternal age, Vitamin D deficiency). (25) Although prospective cohort studies with data pre-dating onset of diabetes are an ideal design for examining such factors they are challenging with a disease of relatively low incidence such as T1DM. Nonetheless, the SDRNT1BIO can yield useful 7 information on the role of environment, for example by examining how the pattern of potential risk factors varies with genotype or auto-antibody phenotype. Accordingly we have collected some lifestyle, environment and pre-diagnosis data. For T1DM complications the SDRNT1BIO and linked e-health record data is being used to explore socio-economic differentials and the impact of health care activities on complications.
Where is it located and how is it funded?
The SDRNT1BIO was established with joint funding from the Scottish Chief Scientist Office and Diabetes UK. The study activities, including protocol development and recruitment of participants, were overseen by a Study Steering Committee including a patient representative, the study funders, and lead diabetes consultants from participating Scottish Health Boards. All data and samples (baseline and prospective) are held at the coordinating centre at the University of Dundee, Scotland UK.
Who is in the cohort? Study Design, Entry criteria and Sampling Frame
Eligibility criteria are summarised in Table 1 . We aimed to recruit a representative sample of all adults aged 16 years and older with a clinical diagnosis of T1DM or with monogenic diabetes (i.e. MODY) or with a diagnosis of latent auto-immune disease of adulthood.
The SDRNT1BIO cohort was established using a cross-sectional design for the study fieldwork with recruitment primarily focused on 10 of 14 NHS Board regions in Scotland 8 ( Table 2 ). The Boards not targeted were excluded because of the envisaged high cost per participant recruited given the remote geographic location and low population density (i.e. Tables 3A and 3B show the distribution of some key characteristics among the SDRNT1BIO recruits compared to the national population from SCI-Diabetes. As shown, the participants are similar to the national population in almost all characteristics. With regard to socioeconomic status, 16% of SDRNT1BIO participants are resident in areas with the most deprived quintile of Scottish Index of Multiple Deprivation (SIMD) scores (a residential area based measure of deprivation) compared to 20% of the total national T1DM population (Table 3B ). (27) As shown in Table 3B , although we sampled from renal clinics to ensure capture of those with end stage renal disease the prevalence of dialysis was 1.2% versus 1.5% nationally and slightly fewer were albuminuric (11%) compared to the national prevalence (19%).
Representativeness

What has been measured?
Baseline data collection took place between 1 December 2010 and 29 November 2013 inclusive, and comprised a single study visit of approximately 30 minutes. Informed consent was documented for all participants. Participants were asked to complete a self-report questionnaire, and had clinical measures and a blood sample taken. Additionally patients were asked to provide a urine sample at the study visit and were provided a sample tube to post back a second urine sample later. Table 4 summarises the items collected.
Established validated questionnaire instruments were used where these were available. We included the physical activity questions from the International Physical Activity 
How often have they been followed up?
A key aim in setting up the cohort was to harness the potential of data linkage to routine electronic health care records as a means of follow up of participants. Such linkage is 11 feasible in Scotland because the health care records of all patients have a unique health care identifier, the Community Health Index (CHI) number. This is assigned at birth or, for those immigrating into Scotland, on registration with a general practitioner (health care is free at the point of delivery so almost all residents register with a general practitioner). All SDRNT1BIO participants were consented for such linkage and their study day data have been linked to capture both retrospective and prospective data specifically: At recruitment, participants were invited to give consent for future face-to-face follow up, to which 93% agreed; as yet we have not taken up this opportunity. Participants were also invited to give consent for having spare blood captured and stored from any future clinical encounters, to which 94% of participants agreed. We have established a mechanism for such spare blood capture for the participants in two of the Health Boards and plan to roll out this collection nationally as part of the GoSHARE Spare Blood Project [http://www.goshare.org.uk/]. To date we hold follow-up EDTA plasma for 300 SDRNT1BIO participants.
What has it found? Initial findings of interest
The initial studies using the biosamples of the bioresource are now underway but here we describe one useful set of information from the questionnaire data. Management of T1DM has changed in recent years with moves towards more frequent use of basal bolus insulin regimens, and pumps, more frequent blood glucose self-testing and carbohydrate counting.
Here we describe the patterns of insulin management and glucose management among the 13 SDRNT1BIO participants and examine associations with gender and socio-economic status.
Socio-economic status was assessed using the SIMD based on address at time of interview divided into quintiles. Three measures of self-reported insulin and glucose management were analysed:
• Insulin Frequency (IF) : < 4 or ≥ 4 injections a day or using pump;
• Blood Glucose Monitoring (BGM) testing : < 4 or ≥ 4 tests a day;
• and carbohydrate counting or exchanges (CC) : yes/no.
Overall 73% (4316) were injecting at least four times daily (IF ≥4) but just 4.6% (269) were using a pump (Table 5 ). Overall 52% (3055) were testing blood glucose at least four times daily (BGM ≥4) and 61% (3552) were using carbohydrate counting or exchange (CC). Men (Table 6 ). All three measures (IF, BGM and CC) were associated with lower mean HbA1c (Table 7) . HbA1c was lower in those in the more affluent areas (beta regression coefficient per SIMD quintile -0.17 (95% CI -0.20,-0.14), P=0.0001 adjusted for age and sex, beta -0.14 (95% CI -0.17,-0.11) on adjustment for glucose management). We conclude that structured patient education programmes aimed at improving self-management, as recommended in our national diabetes strategy, need to explicitly tackle inequalities by sex and deprivation.
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What are the main strengths and weaknesses?
The main strengths of the SDRNT1BIO cohort are: (i) its large size; (ii) the comprehensive retrospective and prospective capture of a wide range of health data; (iii) the large set of biosamples obtained; (iv) that the cohort is being comprehensively genotyped; (v) its broad representativeness of the national adult population with T1DM; (vi) the high rate of consent to future follow up; (vii) the high rate of consent to spare blood capture; and (viii) the low cost of the work given the amount of data collected. Weaknesses are that: (i) only a subset have follow-up biosamples as yet; (ii) lack of funding to date for re-examination; and (iii) need to improve discoverability and infrastructure support for collaborative use.
Can I get hold of the data? Where can I find out more?
The study was carried out in accordance with the ethical principles in the Declaration of The SDRNT1BIO was established to support collaborative research use. We aim to achieve the appropriate balance between fostering use and maintaining the data governance and security of linked data. All data are held in an anonymised form with the file linking study identifier to identifiable patient details held separately and unavailable to researchers. Data 15 are held on a secure server accessible only to approved researchers. Analysis takes place on the server with access via end-to-end encrypted secure shell tunneling. Analysts must have undertaken an approved data security course. A data access committee oversees applications for collaboration. Criteria for approval include having a scientifically justified question, the feasibility and power to address the question in the dataset, whether the question is already being examined using the data, whether the application is a bone fide researcher in a research institution and whether exhaustible material is being requested.
Samples are not issued externally but application can be made to have specified funded measures made if these are scientifically valid and if the question exploits the unique characteristics of the cohort (i.e. cannot be examined in a less extensive resource). In person follow up studies cannot be initiated by external collaborators for privacy reasons but can be proposed as collaborations.
To date biosamples have been used for DNA extraction and genome wide genotyping. 
Profile in a nutshell
• The SDRNT1BIO is one of the largest and most comprehensive collections of biomaterials from people with type 1 diabetes (T1DM) in existence, and has been shown to be representative of the national adult population with T1DM.
• 6,127 adults, aged 16 years or older, with T1DM were recruited from across Scotland between 01/12/2010 and 29/11/2013 with a high rate of consent to future follow up.
• Biosamples include baseline collections of serum, plasma, whole blood and urine alongside follow-up capture of plasma where patients consented to spare blood capture.
• Baseline data includes sociodemographics, details of diabetes diagnosis and treatment, history of complications and lifestyle assessment e.g. physical activity, smoking and alcohol aspects, alongside results from physical measures e.g. anthropometry, bioimpedance, and blood pressure.
• Data linkage to routine electronic health care records has allowed retrospective and prospective data capture across a number of health outcomes including diabetes related care in primary care, renal replacement therapy, outpatient attendance, hospitalizations, cancers and deaths.
The SDRNT1BIO has also been comprehensively genotyped.
• Not currently pregnant (4) Able to give informed consent (5) A label of type 1 diabetes (T1DM), MODY or LADA on SCI-DC database or in clinical record (6) Interval between diagnosis and starting insulin <1 year for patients with diagnosis of T1DM (7) Current use of insulin if diagnosed with T1DM
Exclusion criteria for main study and MODY sub-study (1) Known secondary basis for diabetes e.g. haemochromatosis, pancreatitis, pancreatectomy Blood -non-fasting (n=6005 persons with a sample)
• Serum, Plasma, whole blood in EDTA, whole blood in Paxgene tubes Single urine sample (n=5839 persons with a sample) Two urine samples (n=4902 persons with two or more samples) 
